Race Oncology (ASX:RAC) - Aktienkurs, Nachrichten und Analyse

RAC Aktienübersicht

Race Oncology Limited, ein globales Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Krebsbehandlung.

Über das Unternehmen

RAC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 14.1% pro Jahr sinken.

Die Aktionäre wurden im vergangenen Jahr verwässert

Hat keine nennenswerten Einnahmen (A$6M)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Race Oncology Limited Wettbewerber

Dimerix

ASX:DXB

AU$280.6m

PYC Therapeutics

ASX:PYC

AU$559.9m

Aroa Biosurgery

ASX:ARX

AU$205.7m

Paradigm Biopharmaceuticals

ASX:PAR

AU$89.3m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Race Oncology
Historische Aktienkurse
Aktueller Aktienkurs	AU$1.83
52-Wochen-Hoch	AU$2.09
52-Wochen-Tief	AU$0.64
Beta	1.57
11 Monat Veränderung	27.18%
3 Monate Veränderung	28.52%
1 Jahr Veränderung	48.98%
33 Jahre Veränderung	-49.72%
5 Jahre Veränderung	3,550.00%
Veränderung seit IPO	588.68%

Aktuelle Nachrichten und Updates

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10

Recent updates

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

Aktionärsrenditen

	RAC	AU Biotechs	AU Markt
7D	-0.8%	0.6%	-0.3%
1Y	49.0%	7.6%	8.3%

Rendite im Vergleich zur Industrie: RAC übertraf die Branche Australian Biotechs, die im vergangenen Jahr eine Rendite von -6.6 erzielte.

Rendite vs. Markt: RAC übertraf den Markt Australian, der im vergangenen Jahr eine Rendite von 8.5 erzielte.

Preisvolatilität

Is RAC's price volatile compared to industry and market?
RAC volatility
RAC Average Weekly Movement	10.2%
Biotechs Industry Average Movement	11.8%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	3.2%

Stabiler Aktienkurs: RACDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: RACDie wöchentliche Volatilität (12%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2011	n/a	Daniel Tillett	www.raceoncology.com

Race Oncology Limited, ein globales Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Krebsbehandlung. Sein Hauptprodukt, Bisantren, ist ein niedermolekulares Anthracen-Chemotherapeutikum. Das Unternehmen entwickelt Bisantren, um den ungedeckten Bedarf von Patienten in verschiedenen onkologischen Indikationen zu decken und erforscht die Kombination von Krebsbekämpfung und Herzschutz.

Race Oncology Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Race Oncology im Vergleich zum Marktanteil des Unternehmens?
RAC grundlegende Statistiken
Marktanteil	AU$310.78m
Gewinn(TTM)	-AU$11.17m
Umsatz(TTM)	AU$5.82m

53.4x

Kurs-Umsatz-Verhältnis

-27.8x

Kurs-Gewinn-Verhältnis

Ist RAC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
RAC Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$5.82m
Kosten der Einnahmen	AU$2.87m
Bruttogewinn	AU$2.95m
Sonstige Ausgaben	AU$14.13m
Umsatz	-AU$11.17m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.066
Bruttomarge	50.73%
Nettogewinnspanne	-192.14%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich RAC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

RAC Aktienübersicht

Belohnungen

Risikoanalyse

Race Oncology Limited Wettbewerber

ASX:DXB

AU$280.6m

ASX:PYC

AU$559.9m

ASX:ARX

AU$205.7m

ASX:PAR

AU$89.3m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

Recent updates

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Erträge & Einnahmen